|
H10: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
|
It was learned through implant patient registry that a patient with a 27mm 11060a, implanted in aortic position, underwent a valve-in-valve procedure after an implant duration of 3 years and 1 month due to unknown reasons.The valve was replaced with a 26mm 9755rsl valve.
|
|
H11: additional manufacturer narrative: updated sections: b4, g3, g6, h2, h6 (component code, investigation findings, and investigation conclusions).A device history record (dhr) review was not performed, as no information regarding a device failure mode was provided.Furthermore, there is no allegation of a malfunction which could be related to a manufacturing non-conformance and/or one was not suspected or confirmed through investigation; no labeling non-conformance/deficiency; no device-related infection; and no evidence of a product failure with regard to design, reliability, or use error ((b)(4)).Engineering evaluation summary: the complaint investigation was conducted, using evaluation summary (b)(4) and triage level 1, in accordance with (b)(4).Due diligence attempts were made to gather additional information regarding a device failure mode, however additional information is not available at this time.Patient medical records were not provided by the hospital for review, or the medical records provided do not clarify the device failure mode.Per the instructions for use (ifu), reoperation/explant are known potential adverse events associated with bioprosthetic cardiac valves and annuloplasty rings.In this case, there is no evidence of a malfunction which could be related to a manufacturing non-conformance and/or one was not suspected or confirmed through investigation; no labeling non-conformance/deficiency; no use-related issue with a hazardous situation; no device-related infection; and no evidence of a product failure with regard to design, reliability, or use error.As such, neither a product risk assessment (pra) nor corrective or preventive actions (capa/scar) are required at this time, per (b)(4).Based on the information available, a definitive root cause cannot be conclusively determined.H11: corrective data: the component code submitted under the initial medwatch# (b)(4) was in err.The correct code has been updated, and this correction is being submitted all pertinent information available to edwards lifesciences has been submitted.
|